Vaccines
New studies come out regularly supporting the efficacy and safety of the COVID-19 vaccines. Here’s a look as well as other COVID-19 news.
While some get the jab faithfully each flu season, about half of the American population declines, likely over doubts of the vaccine’s effectiveness and necessity.
Researchers aren’t sure why the mRNA vaccines appear to cause myocarditis symptoms. The FDA said the risk appears more after the second dose. Find more here.
Moderna reported its third-quarter earnings, and since it currently only has one commercial product, its COVID-19 vaccine, that was the financial focus.
Vaccinations will be required by January 4 under the new White House plan.
Merck and Ridgeback Biotherapeutics’ antiviral drug molnupiravir, which showed great promise against COVID-19 in clinical trials, received its first authorization.
Both Moderna and Pfizer reported third-quarter financials this week, and it was instantly obvious that the COVID-19 vaccines are huge profit drivers for the companies.
While some may wonder about the commercial future of these late-to-the-market solutions, the developers themselves are taking a long view.
The decision follows a 14-0 vote among members of an expert panel advising the agency.
Pfizer reported its third-quarter 2021 financials, citing $24.1 billion in quarterly revenues, a stunning 130% operational growth.
PRESS RELEASES